Galapagos NV (GLPG)

NASDAQ: GLPG · IEX Real-Time Price · USD
52.23
-1.45 (-2.70%)
At close: Aug 18, 2022 4:00 PM
51.50
-0.73 (-1.40%)
After-hours: Aug 18, 2022 7:22 PM EDT
-2.70%
Market Cap 3.52B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 67.39M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 169,235
Open 53.57
Previous Close 53.68
Day's Range 52.16 - 53.57
52-Week Range 46.41 - 72.11
Beta 0.24
Analysts Buy
Price Target 66.74 (+27.8%)
Earnings Date Aug 4, 2022

About GLPG

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoart... [Read more...]

Industry Biotechnology
IPO Date May 6, 2005
CEO Onno van de Stolpe
Employees 1,344
Stock Exchange NASDAQ
Ticker Symbol GLPG
Full Company Profile

Financial Performance

In 2021, Galapagos NV's revenue was 484.85 million, an increase of 1.42% compared to the previous year's 478.05 million. Losses were -103.23 million, -66.20% less than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for GLPG stock is "Buy." The 12-month stock price forecast is 66.74, which is an increase of 27.78% from the latest price.

Price Target
$66.74
(27.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 1 8 August 202 2 , 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 8 August 2022, 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC .

First key steps in pipeline rebuild and strong commercial progress in H1 2022

Webcast presentation tomorrow , 5 August 202 2 , at 1 4 .00 CET / 8 AM ET, www.glpg.com ,

Are Medical Stocks Lagging Galapagos (GLPG) This Year?

Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies

Webcast presentation tomorrow, Wednesday , 22 June 2022 , at 14 .00 CET / 8 AM ET, www.glpg.com

Galapagos increases share capital through subscription right exercises

Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?

The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...

Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?

Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine's Spectra™ Pla...

WALTHAM, Mass.--(BUSINESS WIRE)-- #biotech--Galapagos in-licenses novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher Medicine's Spectra™ Platform.

Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?

Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year?

Here is how Galapagos NV (GLPG) and MedAvail Holdings, Inc. (MDVL) have performed compared to their sector so far this year.

Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength?

Galapagos NV (GLPG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ...

Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders' meetings

-- Proposal of one-tier board structure & appointment of three new directors -- Mechelen, Belgium; 24 March 2022, 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published it...

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

KRAKOW, Poland, March 15, 2022 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targ...

Galapagos receives transparency notification from EcoR1 Capital

Mechelen, Belgium; 03 February 2022, 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from EcoR1 Capital , LLC .

Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn's and Colitis Orga...

Mechelen, Belgium; 2 February 2022, 22.01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) will present d ata at the European Crohn's and Colitis Organization (ECCO) annual congress taking place 16-19 Febru...

Why Galapagos Trounced the Market Today

A high-profile healthcare industry executive has been tapped as the company's new CEO.

Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO

Belgian drugmaker Galapagos NV on Wednesday named former Johnson & Johnson senior executive Paul Stoffels as its chief executive officer, effective April 1.

Galapagos creates new subscription right plan

Mechelen, Belgium; 26 January 2022, 22 .40  CET; regulated information – Galapagos   NV (Euronext & NASDAQ: GLPG) announced today that its supervisory b oard created 1,000,000 subscription rights under ...

Galapagos appoints Paul Stoffels as Chief Executive Officer

Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement

Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; 6 January 2022, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40 th A nnual J.P. Morgan Healthcare Conference on January 10-13 , 20 22.

Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

Mechelen, Belgium; 22 November 2021 , 22. 01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 i...

Galapagos reports commercial and operational progress at Q3 financial results

Webcast presentation tomorrow , 5 November 202 1 , at 1 3 .00 CET / 8 AM ET, www.glpg.com , +32 2 793 38 47 , code 4987105

Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study

Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.

Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients

Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).  The analyses showed clinical benefi...